

Supplemental Online Content

Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5- α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. *JAMA Dermatol*. Published online February 2, 2022. doi:10.1001/jamadermatol.2021.5743

eAppendix 1. Terminal and Vellus Hair (Basic Description)

eAppendix 2. Estimation of Surface Under the Cumulative Ranking Curve (SUCRA)

eFigure 1. Network Plot for Outcome 1, Change in Total Hair Count (per cm²) After 24 Weeks of Therapy

eFigure 2. Network Plot for Outcome 2, Change in Terminal Hair Count (per cm²) After 24 Weeks of Therapy

eFigure 3. Network Plot for Outcome 3, Change in Total Hair Count (per cm²) After 48 Weeks of Therapy

eFigure 4. Network Plot for Outcome 4, Change in Terminal Hair Count (per cm²) After 48 Weeks of Therapy

eTable 1. Quality of Evidence Assessment for the Network of Outcome 1, Change in Total Hair Count (per cm²) After 24 Weeks of Therapy for Male Pattern Hair Loss

eTable 2. Quality of Evidence Assessment for the Network of Outcome 2, Change in Terminal Hair Count (per cm²) After 24 Weeks of Therapy for Male Androgenetic Alopecia

eTable 3. Quality of Evidence Assessment for the Network of Outcome 3, Change in Total Hair Count (per cm²) After 48 Weeks of Therapy for Male Androgenetic Alopecia

eTable 4. Quality of Evidence Assessment for the Network of Outcome 4, Change in Terminal Hair Count (per cm²) After 48 Weeks of Therapy for Male Androgenetic Alopecia

eTable 5. Demographics of Patients From Studies Included in Quantitative Analyses

eFigure 5. League Table for Our First Endpoint (i.e., 'Outcome 1')

eFigure 6. League Table for Our Second Endpoint (i.e., 'Outcome 2')

eFigure 7. League Table for Our Third Endpoint (i.e., 'Outcome 3')

eFigure 8. League Table for Our Fourth Endpoint (i.e., 'Outcome 4')

eFigure 9. Presentation of Treatments' Surface Under the Cumulative Ranking Curve (SUCRA) Via A Modified Kilim Plot for Data From Only Randomized Trials and Both Randomized and Observational Studies.

eFigure 10. League Table for Our First Endpoint (i.e., 'Outcome 1') Based on Solely on Data From Randomized Studies

eFigure 11. League Table for Our Second Endpoint (i.e., 'Outcome 2') Based on Solely on Data From Randomized Studies

eFigure 12. Presentation of Treatments' Surface Under the Cumulative Ranking Curve (SUCRA) Via A Modified Kilim Plot for 'Outcome 1' in Patients With: (1) any Level of

Severity, (2) Mild Form of the Condition, (3) Moderate Form of the Condition, and (4) Severe Form of the Condition

eFigure 13. Presentation of Treatments' Surface Under the Cumulative Ranking Curve (SUCRA) Via A Modified Kilim Plot for 'Outcome 2' in Patients With: (1) any Level of Severity, (2) Mild Form of the Condition, (3) Moderate Form of the Condition, and (4) Severe Form of the Condition

eFigure 14. Presentation of Treatments' Surface Under the Cumulative Ranking Curve (SUCRA) Via A Modified Kilim Plot for 'Outcome 3' in Patients With: (1) any Level of Severity, (2) Mild Form of the Condition, (3) Moderate Form of the Condition, and (4) Severe Form of the Condition

eFigure 15. Presentation of Treatments' Surface Under the Cumulative Ranking Curve (SUCRA) Via A Modified Kilim Plot for 'Outcome 4' in Patients With: (1) any Level of Severity, (2) Mild Form of the Condition, (3) Moderate Form of the Condition, and (4) Severe Form of the Condition

eFigure 16. League Table for Our First Endpoint (i.e., 'Outcome 1')(for Androgenetic Alopecia That Is MILD)

eFigure 17. League Table for Our First Endpoint (i.e., 'Outcome 1') (for Androgenetic Alopecia That Is MODERATE)

eFigure 18. League Table for Our First Endpoint (i.e., 'Outcome 1') (for Androgenetic Alopecia That Is SEVERE)

eFigure 19. League Table for Our Second Endpoint (i.e., 'Outcome 2') (for Androgenetic Alopecia That Is MILD)

eFigure 20. League Table for Our Second Endpoint (i.e., 'Outcome 2') (for Androgenetic Alopecia That Is MODERATE)

eFigure 21. League Table for Our Second Endpoint (i.e., 'Outcome 2') (for Androgenetic Alopecia That Is SEVERE)

eFigure 22. League Table for Our Third Endpoint (i.e., 'Outcome 3') (for Androgenetic Alopecia That Is MILD)

eFigure 23. League Table for Our Third Endpoint (i.e., 'Outcome 3') (for Androgenetic Alopecia That Is MODERATE)

eFigure 24. League Table for Our Third Endpoint (i.e., 'Outcome 3') (for Androgenetic Alopecia That Is SEVERE)

eFigure 25. League Table for Our Fourth Endpoint (i.e., 'Outcome 4') (for Androgenetic Alopecia That Is MILD)

eFigure 26. League Table for Our Fourth Endpoint (i.e., 'Outcome 4') (for Androgenetic Alopecia That Is MODERATE)

eFigure 27. League Table for Our Fourth Endpoint (i.e., 'Outcome 4') (for Androgenetic Alopecia That Is SEVERE)

eReferences

This supplemental material has been provided by the authors to give readers additional information about their work.

eAppendix A. Terminal and vellus hair (basic description)


The various types of hair include vellus and terminal;¹ the defining length for these two has been subject to debate.^{2,3} However, according to Whiting (2008),¹ terminal hair—such as eyebrows and beards—has a diameter greater than 60 micrometres, and is longer than 2 millimetres. Cranial hair is terminal.¹ Whiting (2008) describes vellus hair to be less than 30 micrometres in diameter, and less than 2 millimetres long;¹ furthermore, it can transform to the terminal type.¹ The scalp constitutes vellus and terminal hair—with the latter being more preponderant.¹ Total hair count—on the scalp—mainly constitutes vellus and terminal hair per unit area.

eAppendix B. Estimation of surface under the cumulative ranking curve (SUCRA)


Rank probabilities were generated, and these were used to compute a treatment's surface under the cumulative ranking curve (SUCRA) value according to the following formula:

$$SUCRA_k = \frac{\sum_{c=1}^{b-1} Cum_{k,c}}{b-1}$$


where k , c , and b represent a drug of interest, a drug's rank probability and total number of drugs in the network, respectively. A drug's SUCRA (i.e., $SUCRA_k$) is between 0% and 100% (or 0 and 1) inclusive.




eFigure 1. Network plot for outcome 1, change in total hair count (per cm²) after 24 weeks of therapy. Network plots are characterized by nodes and edges. Nodes correspond to an intervention. Edges correspond to the lines between two nodes that represent a comparison from direct evidence. The number of studies contributing to direct evidence are listed on the edges.



eFigure 2. Network plot for outcome 2, change in terminal hair count (per cm²) after 24 weeks of therapy. Network plots are characterized by nodes and edges. Nodes correspond to an intervention. Edges correspond to the lines between two nodes that represent a comparison from direct evidence. The number of studies contributing to direct evidence are listed on the edges.



eFigure 3. Network plot for outcome 3, change in total hair count (per cm²) after 48 weeks of therapy. Network plots are characterized by nodes and edges. Nodes correspond to an intervention. Edges correspond to the lines between two nodes that represent a comparison from direct evidence. The number of studies contributing to direct evidence are listed on the edges.



eFigure 4. Network plot for outcome 4, change in terminal hair count (per cm²) after 48 weeks of therapy. Network plots are characterized by nodes and edges. Nodes correspond to an intervention. Edges correspond to the lines between two nodes that represent a comparison from direct evidence. The number of studies contributing to direct evidence are listed on the edges.

eTable 1. Quality of evidence assessment for the network of outcome 1, change in total hair count (per cm²) after 24 weeks of therapy for male pattern hair loss

Comparison	Number of studies	Confidence rating [†]
dutasteride(oral)0.02mg : dutasteride(oral)0.1mg	1	Low ^{1b,5b,6b}
dutasteride(oral)0.02mg : dutasteride(oral)0.5mg	1	Moderate ^{1b}
dutasteride(oral)0.02mg : finasteride(oral)1mg	1	Moderate ^{1b,5b,6a}
dutasteride(oral)0.02mg : minoxidil(oral)0.25mg	1	Low ^{1b,4a,5a,6b}
dutasteride(oral)0.02mg : vehicle or placebo	1	Moderate ^{1b,5b}
dutasteride(oral)0.1mg : dutasteride(oral)0.5mg	1	Moderate ^{1b,5b}
dutasteride(oral)0.1mg : finasteride(oral)1mg	1	Moderate ^{1b,5b,6a}
dutasteride(oral)0.1mg : minoxidil(oral)0.25mg	1	Low ^{1b,5a,6b}
dutasteride(oral)0.1mg : vehicle or placebo	1	Moderate ^{1b,5a}
dutasteride(oral)0.5mg : finasteride(oral)1mg	2	Low ^{1b,5a,6a}
dutasteride(oral)0.5mg : minoxidil(oral)0.25mg	1	Moderate ^{1b,6b}
dutasteride(oral)0.5mg : vehicle or placebo	2	Moderate ^{1b}
finasteride(oral)0.2mg : finasteride(oral)1mg	1	Moderate ^{1a,4b}
finasteride(oral)0.2mg : vehicle or placebo	1	High
finasteride(oral)1mg : finasteride(topical)1%	1	Low ^{1a,5b,6b}
finasteride(oral)1mg : minoxidil(oral)0.25mg	1	Moderate ^{1b,5a,6b}
finasteride(oral)1mg : vehicle or placebo	4	Low ^{1b,5a,6b}
finasteride(oral)5mg : vehicle or placebo	1	Low ^{1a,6b}
minoxidil(oral)0.25mg : vehicle or placebo	1	Moderate ^{1b,4b,6b}
minoxidil(oral)5mg : minoxidil(topical)3%	1	Low ^{1b,4b,6b}
minoxidil(topical)0.1% : minoxidil(topical)1%	1	Low ^{1a,4a,5a,6b}
minoxidil(topical)0.1% : minoxidil(topical)2%	1	High
minoxidil(topical)0.1% : vehicle or placebo	1	Moderate ^{1a,4b}
minoxidil(topical)1% : minoxidil(topical)2%	1	Moderate ^{1a,5b,6b}
minoxidil(topical)1% : minoxidil(topical)5%	1	Low ^{1a,5b,6b}
minoxidil(topical)1% : vehicle or placebo	1	High
minoxidil(topical)2% : minoxidil(topical)3%	1	Moderate ^{1a,5b,6b}

minoxidil(topical)2% : vehicle or placebo	6	Moderate ^{1a,5a,6b}
dutasteride(oral)0.02mg : finasteride(oral)0.2mg	0	Low ^{1b,5b,6b}
dutasteride(oral)0.02mg : finasteride(oral)5mg	0	Low ^{1b,5a,6b}
dutasteride(oral)0.02mg : finasteride(topical)1%	0	Very low ^{1b,5b,6b}
dutasteride(oral)0.02mg : minoxidil(oral)5mg	0	Very low ^{1b,4b,6b}
dutasteride(oral)0.02mg : minoxidil(topical)0.1%	0	Low ^{1b,4a,5a,6b}
dutasteride(oral)0.02mg : minoxidil(topical)1%	0	Low ^{1b,4b,6b}
dutasteride(oral)0.02mg : minoxidil(topical)2%	0	Low ^{1b,5b,6b}
dutasteride(oral)0.02mg : minoxidil(topical)3%	0	Low ^{1a,4b,6b}
dutasteride(oral)0.02mg : minoxidil(topical)5%	0	Low ^{1a,4a,5a,6b}
dutasteride(oral)0.1mg : finasteride(oral)0.2mg	0	Very low ^{1b,4a,5a,6b}
dutasteride(oral)0.1mg : finasteride(oral)5mg	0	Very low ^{1b,4a,5a,6b}
dutasteride(oral)0.1mg : finasteride(topical)1%	0	Very low ^{1b,5b,6b}
dutasteride(oral)0.1mg : minoxidil(oral)5mg	0	Very low ^{1b,4a,5a,6b}
dutasteride(oral)0.1mg : minoxidil(topical)0.1%	0	Low ^{1b,5b,6b}
dutasteride(oral)0.1mg : minoxidil(topical)1%	0	Low ^{1b,4b,6b}
dutasteride(oral)0.1mg : minoxidil(topical)2%	0	Very low ^{1b,4a,5a,6b}
dutasteride(oral)0.1mg : minoxidil(topical)3%	0	Low ^{1a,5b,6b}
dutasteride(oral)0.1mg : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
dutasteride(oral)0.5mg : finasteride(oral)0.2mg	0	Low ^{1b,5b,6b}
dutasteride(oral)0.5mg : finasteride(oral)5mg	0	Low ^{1b,4a,5a,6b}
dutasteride(oral)0.5mg : finasteride(topical)1%	0	Low ^{1b,5b,6b}
dutasteride(oral)0.5mg : minoxidil(oral)5mg	0	Low ^{1b,5b,6b}
dutasteride(oral)0.5mg : minoxidil(topical)0.1%	0	Low ^{1b,6b}
dutasteride(oral)0.5mg : minoxidil(topical)1%	0	Low ^{1b,4a,5a,6b}
dutasteride(oral)0.5mg : minoxidil(topical)2%	0	Low ^{1b,5b,6b}
dutasteride(oral)0.5mg : minoxidil(topical)3%	0	Low ^{1a,5a,6b}
dutasteride(oral)0.5mg : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
finasteride(oral)0.2mg : finasteride(oral)5mg	0	Low ^{1a,4a,5a,6b}
finasteride(oral)0.2mg : finasteride(topical)1%	0	Low ^{1a,4b,6b}

finasteride(oral)0.2mg : minoxidil(oral)0.25mg	0	Low ^{1b,5b,6b}
finasteride(oral)0.2mg : minoxidil(oral)5mg	0	Low ^{1a,4a,5a,6b}
finasteride(oral)0.2mg : minoxidil(topical)0.1%	0	Low ^{1a,5b,6b}
finasteride(oral)0.2mg : minoxidil(topical)1%	0	Low ^{1a,4b,6b}
finasteride(oral)0.2mg : minoxidil(topical)2%	0	Low ^{1a,4a,5a,6b}
finasteride(oral)0.2mg : minoxidil(topical)3%	0	Low ^{1a,4a,5a,6b}
finasteride(oral)0.2mg : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
finasteride(oral)1mg : finasteride(oral)5mg	0	Low ^{1b,4a,5a,6b}
finasteride(oral)1mg : minoxidil(oral)5mg	0	Low ^{1b,4a,5a,6b}
finasteride(oral)1mg : minoxidil(topical)0.1%	0	Low ^{1b,5b,6b}
finasteride(oral)1mg : minoxidil(topical)1%	0	Low ^{1b,4b,6b}
finasteride(oral)1mg : minoxidil(topical)2%	0	Low ^{1b,5b,6b}
finasteride(oral)1mg : minoxidil(topical)3%	0	Low ^{1a,5b,6b}
finasteride(oral)1mg : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
finasteride(oral)5mg : finasteride(topical)1%	0	Low ^{1a,4a,5a,6b}
finasteride(oral)5mg : minoxidil(oral)0.25mg	0	Low ^{1b,5a,6b}
finasteride(oral)5mg : minoxidil(oral)5mg	0	Low ^{1a,5b,6b}
finasteride(oral)5mg : minoxidil(topical)0.1%	0	Low ^{1a,5a,6b}
finasteride(oral)5mg : minoxidil(topical)1%	0	Low ^{1a,4a,5a,6b}
finasteride(oral)5mg : minoxidil(topical)2%	0	Low ^{1a,5b,6b}
finasteride(oral)5mg : minoxidil(topical)3%	0	Low ^{1a,5b,6b}
finasteride(oral)5mg : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
finasteride(topical)1% : minoxidil(oral)0.25mg	0	Low ^{1b,5b,6b}
finasteride(topical)1% : minoxidil(oral)5mg	0	Low ^{1a,4a,5a,6b}
finasteride(topical)1% : minoxidil(topical)0.1%	0	Low ^{1a,5b,6b}
finasteride(topical)1% : minoxidil(topical)1%	0	Low ^{1a,4b,6b}
finasteride(topical)1% : minoxidil(topical)2%	0	Low ^{1a,5b,6b}
finasteride(topical)1% : minoxidil(topical)3%	0	Low ^{1a,5b,6b}
finasteride(topical)1% : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
finasteride(topical)1% : vehicle or placebo	0	Low ^{1b,5a,6b}

minoxidil(oral)0.25mg : minoxidil(oral)5mg	0	Very low ^{1b,4b,6b}
minoxidil(oral)0.25mg : minoxidil(topical)0.1%	0	Low ^{1b,4b,6b}
minoxidil(oral)0.25mg : minoxidil(topical)1%	0	High
minoxidil(oral)0.25mg : minoxidil(topical)2%	0	Low ^{1b,5b,6b}
minoxidil(oral)0.25mg : minoxidil(topical)3%	0	Low ^{1b,4b,6b}
minoxidil(oral)0.25mg : minoxidil(topical)5%	0	Low ^{1a,5b,6b}
minoxidil(oral)5mg : minoxidil(topical)0.1%	0	Low ^{1a,4b,6b}
minoxidil(oral)5mg : minoxidil(topical)1%	0	Low ^{1a,4b,6b}
minoxidil(oral)5mg : minoxidil(topical)2%	0	Very low ^{1b,4a,5a,6b}
minoxidil(oral)5mg : minoxidil(topical)5%	0	Low ^{1a,4a,5a,6b}
minoxidil(oral)5mg : vehicle or placebo	0	Low ^{1a,4b,6b}
minoxidil(topical)0.1% : minoxidil(topical)3%	0	Low ^{1a,4b,6b}
minoxidil(topical)0.1% : minoxidil(topical)5%	0	Low ^{1a,5a,6b}
minoxidil(topical)1% : minoxidil(topical)3%	0	Low ^{1a,4b,6b}
minoxidil(topical)2% : minoxidil(topical)5%	0	Low ^{1a,4b,6b}
minoxidil(topical)3% : minoxidil(topical)5%	0	Low ^{1a,4a,5a,6b}
minoxidil(topical)3% : vehicle or placebo	0	Low ^{1a,4a,5a,6b}
minoxidil(topical)5% : vehicle or placebo	0	Low ^{1a,5b,6b}

†The confidence rating is an overall qualitative assessment which summarizes judgement across 6 domains that impact quality of evidence (i.e., within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence). Confidence rating was done with the web application called ‘Confidence In Network Meta-Analysis’ (CINeMA). The superscript numbers correspond to the following reasons for downgrading confidence ratings:

- (1) within-study bias,
- (2) reporting bias,
- (3) indirectness,
- (4) imprecision,
- (5) heterogeneity, and
- (6) incoherence.

Each of the six domains can be qualitatively judged as having ‘no concerns’, ‘some concerns’, or ‘major concerns’. The confidence rating—which is the overall judgement—can be either “Very low”, “Low”, “Moderate” or “High”. Given the concern level, and domain, downgrading of overall confidence rating can be due to the combinations presented in the table below:

Domain	“Concern level”	
	a	b
1 (within-study bias)	Some concern	Major concern
2 (reporting bias)	Some concern	Major concern
3 (indirectness)	Some concern	Major concern

4 (imprecision)	Some concern	Major concern
5 (heterogeneity)	Some concern	Major concern
6 (incoherence)	Some concern	Major concern

E.g., for an overall confidence rating of “Low”, downgrading—in the case of the “minoxidil(topical)5%: vehicle or placebo” comparison—was due to: some concerns for within-study bias—which corresponded to 1a, major concerns for heterogeneity—which corresponded to 5b, and major concerns for incoherence—which corresponded to 6b.

eTable 2. Quality of evidence assessment for the network of outcome 2, change in terminal hair count (per cm²) after 24 weeks of therapy for male androgenetic alopecia

Comparison	Number of studies	Confidence rating [†]
finasteride(oral)1mg : finasteride(topical)1%	1	Moderate ^{1a,5b}
finasteride(oral)1mg : minoxidil(oral)5mg	1	Low ^{1b,5b}
finasteride(oral)1mg : minoxidil(topical)2%	1	Low ^{1b,5a}
minoxidil(oral)0.25mg : vehicle or placebo	1	Low ^{1b,4a,5a}
minoxidil(oral)5mg : minoxidil(topical)2%	1	Low ^{1b}
minoxidil(topical)0.1% : minoxidil(topical)1%	2	Moderate ^{1a,4a,5a}
minoxidil(topical)0.1% : minoxidil(topical)2%	2	High
minoxidil(topical)0.1% : vehicle or placebo	2	Moderate ^{1a,5b}
minoxidil(topical)1% : minoxidil(topical)2%	2	Moderate ^{1a,5b}
minoxidil(topical)1% : minoxidil(topical)5%	1	Moderate ^{1a,5b}
minoxidil(topical)1% : vehicle or placebo	2	Low ^{1a,4a}
minoxidil(topical)2% : vehicle or placebo	6	High
finasteride(oral)1mg : minoxidil(oral)0.25mg	0	Moderate ^{1b}
finasteride(oral)1mg : minoxidil(topical)0.1%	0	High
finasteride(oral)1mg : minoxidil(topical)1%	0	High
finasteride(oral)1mg : minoxidil(topical)5%	0	Moderate ^{1a,5a}
finasteride(oral)1mg : vehicle or placebo	0	Moderate ^{1b}
finasteride(topical)1% : minoxidil(oral)0.25mg	0	Moderate ^{1b}
finasteride(topical)1% : minoxidil(oral)5mg	0	Moderate ^{1b,4b}
finasteride(topical)1% : minoxidil(topical)0.1%	0	High
finasteride(topical)1% : minoxidil(topical)1%	0	Moderate ^{1a,5a}
finasteride(topical)1% : minoxidil(topical)2%	0	Moderate ^{1b,5a}
finasteride(topical)1% : minoxidil(topical)5%	0	Moderate ^{1a,5b}
finasteride(topical)1% : vehicle or placebo	0	High
minoxidil(oral)0.25mg : minoxidil(oral)5mg	0	Moderate ^{1b}
minoxidil(oral)0.25mg : minoxidil(topical)0.1%	0	Moderate ^{1a,4a,5a}
minoxidil(oral)0.25mg : minoxidil(topical)1%	0	Moderate ^{1a,4a,5a}

minoxidil(oral)0.25mg : minoxidil(topical)2%	0	Moderate ^{1b,5a}
minoxidil(oral)0.25mg : minoxidil(topical)5%	0	Moderate ^{1a,5b}
minoxidil(oral)5mg : minoxidil(topical)0.1%	0	High
minoxidil(oral)5mg : minoxidil(topical)1%	0	High
minoxidil(oral)5mg : minoxidil(topical)5%	0	High
minoxidil(oral)5mg : vehicle or placebo	0	Moderate ^{1b}
minoxidil(topical)0.1% : minoxidil(topical)5%	0	Moderate ^{1a,5b}
minoxidil(topical)2% : minoxidil(topical)5%	0	Moderate ^{1a,5b}
minoxidil(topical)5% : vehicle or placebo	0	Moderate ^{1a,5a}

†The confidence rating is an overall qualitative assessment which summarizes judgement across 6 domains that impact quality of evidence (i.e., within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence). Confidence rating was done with the web application called ‘Confidence In Network Meta-Analysis’ (CINeMA). The following superscript numbers correspond to reasons for downgrading confidence ratings:

- (1) within-study bias,
- (2) reporting bias,
- (3) indirectness,
- (4) imprecision,
- (5) heterogeneity, and
- (6) incoherence.

Each of the six domains can be qualitatively judged as having ‘no concerns’, ‘some concerns’, or ‘major concerns’. The confidence rating—which is the overall judgement—can be either “Very low”, “Low”, “Moderate” or “High”. Given the concern level, and domain, downgrading of overall confidence rating can be due to the combinations presented in the table below:

Domain	“Concern level”	
	a	b
1 (within-study bias)	Some concern	Major concern
2 (reporting bias)	Some concern	Major concern
3 (indirectness)	Some concern	Major concern
4 (imprecision)	Some concern	Major concern
5 (heterogeneity)	Some concern	Major concern
6 (incoherence)	Some concern	Major concern

E.g., for an overall confidence rating of “Low”, downgrading—in the case of the “minoxidil(topical)5%: vehicle or placebo” comparison—was due to: some concerns for within-study bias—which corresponded to 1a, and some concerns for heterogeneity—which corresponded to 5a.

eTable 3. Quality of evidence assessment for the network of outcome 3, change in total hair count (per cm²) after 48 weeks of therapy for male androgenetic alopecia

Comparison	Number of studies	Confidence rating [†]
finasteride(oral)1mg : minoxidil(topical)2%	1	Very low ^{1b,5b,6b}
finasteride(oral)1mg : vehicle or placebo	3	Low ^{1a,5b,6b}
finasteride(oral)5mg : vehicle or placebo	1	Low ^{1a,5b,6b}
minoxidil(topical)2% : minoxidil(topical)3%	2	Low ^{1a,4a,5a,6b}
finasteride(oral)1mg : finasteride(oral)5mg	0	Low ^{1a,4a,5a,6b}
finasteride(oral)1mg : minoxidil(topical)3%	0	Very low ^{1b,5b,6b}
finasteride(oral)5mg : minoxidil(topical)2%	0	Low ^{1a,5b,6b}
finasteride(oral)5mg : minoxidil(topical)3%	0	Low ^{1a,5b,6b}
minoxidil(topical)2% : vehicle or placebo	0	Very low ^{1b,4b,6b}
minoxidil(topical)3% : vehicle or placebo	0	Low ^{1a,4b,6b}

[†]The confidence rating is an overall qualitative assessment which summarizes judgement across 6 domains that impact quality of evidence (i.e., within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence). Confidence rating was done with the web application called ‘Confidence In Network Meta-Analysis’ (CINeMA). The following superscript numbers correspond to reasons for downgrading confidence ratings:

- (1) within-study bias,
- (2) reporting bias,
- (3) indirectness,
- (4) imprecision,
- (5) heterogeneity, and
- (6) incoherence.

Each of the six domains can be qualitatively judged as having ‘no concerns’, ‘some concerns’, or ‘major concerns’. The confidence rating—which is the overall judgement—can be either “Very low”, “Low”, “Moderate” or “High”. Given the concern level, and domain, downgrading of overall confidence rating can be due to the combinations presented in the table below:

Domain	“Concern level”	
	a	b
1 (within-study bias)	Some concern	Major concern
2 (reporting bias)	Some concern	Major concern
3 (indirectness)	Some concern	Major concern
4 (imprecision)	Some concern	Major concern
5 (heterogeneity)	Some concern	Major concern
6 (incoherence)	Some concern	Major concern

E.g., for an overall confidence rating of “Low”, downgrading—in the case of the “minoxidil(topical)3%: vehicle or placebo” comparison—was due to: some concerns for within-study bias—which corresponded to 1a, major concerns for imprecision—which corresponded to 4b, and major concerns for incoherence—which corresponded to 6b

eTable 4. Quality of evidence assessment for the network of outcome 4, change in terminal hair count (per cm²) after 48 weeks of therapy for male androgenetic alopecia

Comparison	Number of studies	Confidence rating [†]
finasteride(oral)1mg : minoxidil(topical)2%	1	Low ^{1b}
minoxidil(topical)2% : minoxidil(topical)3%	1	Moderate ^{1a}
minoxidil(topical)2% : minoxidil(topical)5%	1	Moderate ^{1a}
minoxidil(topical)2% : vehicle or placebo	1	Moderate ^{1a}
minoxidil(topical)5% : vehicle or placebo	1	Moderate ^{1a}
finasteride(oral)1mg : minoxidil(topical)3%	0	Low ^{1b}
finasteride(oral)1mg : minoxidil(topical)5%	0	Low ^{1b}
finasteride(oral)1mg : vehicle or placebo	0	Low ^{1b}
minoxidil(topical)3% : minoxidil(topical)5%	0	Low ^{1b}
minoxidil(topical)3% : vehicle or placebo	0	Low ^{1b}

†The confidence rating is an overall qualitative assessment which summarizes judgement across 6 domains that impact quality of evidence (i.e., within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence). Confidence rating was done with the web application called ‘Confidence In Network Meta-Analysis’ (CINeMA). The following superscript numbers correspond to reasons for downgrading confidence ratings:

- (1) within-study bias,
- (2) reporting bias,
- (3) indirectness,
- (4) imprecision,
- (5) heterogeneity, and
- (6) incoherence.

Each of the six domains can be qualitatively judged as having ‘no concerns’, ‘some concerns’, or ‘major concerns’. The confidence rating—which is the overall judgement—can be either “Very low”, “Low”, “Moderate” or “High”. Given the concern level, and domain, downgrading of overall confidence rating can be due to the combinations presented in the table below:

Domain	“Concern level”	
	a	b
1 (within-study bias)	Some concern	Major concern
2 (reporting bias)	Some concern	Major concern
3 (indirectness)	Some concern	Major concern
4 (imprecision)	Some concern	Major concern
5 (heterogeneity)	Some concern	Major concern
6 (incoherence)	Some concern	Major concern

E.g., for an overall confidence rating of “Moderate”, downgrading—in the case of the “minoxidil(topical)5%: vehicle or placebo” comparison—was due to: some concerns for within-study bias—which corresponded to 1a.

eTable 5. Demographics of patients from studies included in quantitative analyses.

Author(s)	Year of publication	Severity† (proportion of subjects with mild, moderate or severe AGA)			Mean age (in years); SD
		Mild	Moderate	Severe	
Olsen et al	1985	0	0.69	0.31	36.2; 6.05
Olsen et al	1986	0	1	0	36.0; 5.89
Civatte et al	1987	0	0.66	0.34	34.09; 6.56
Koperski et al	1987	No information			38.3; 7.5
Shupack et al	1987	0	1	0	32.91; 5.62
Anderson	1988	0	1	0	32.8; 7.5
Dutrée-Meulenberg et al	1988	0	1	0	34.3; 7.5
Petzoldt	1988	0	1	0	32.9; 8
Rushton et al	1989	No information			18 to 49 years
Kaufman et al	1998	0.15	0.54	0.31	32.50; 1.31
Leyden et al	1999	0.47	0.53	0	32.51; 0.64
Roberts et al	1999	0	1	0	30; 0.38
Van Neste et al	2000	0.505	0.354	0.141	29.75; 0.75
Olsen et al	2002	0.003	0.779	0.218	36.44; 6.43
Saraswat & Kumar	2003	0	0.87	0.13	28.38; 0.85
Hajheydari et al	2009	No information			22.8; 3.3
Tsuboi et al	2009	0.323	0.670	0.007	40.6; 6.64
Eun et al	2010	0	0.71	0.29	38.10; 6.83
Gubelin Harcha et al	2014	0	0.76	0.24	38.50; 7.80
Shanshawal et al	2017	0	0.736	0.264	27.85; 5.5
Suchonwanit et al	2018	0	0.7	0.3	41.78; 12.30
Panchaprateep & Lueangarun	2020	0	0.67	0.33	38; 10
Pirmez & Salas-Callo	2020	No information			36.7; 7.5

Note:

Abbreviations: AGA: androgenetic alopecia, SD: standard deviation

†Mild, Moderate and Severe androgenetic alopecia mainly referred to the Hamilton-Norwood (1) I – II, (2) III – IV, and (3) V or above, respectively.

dutasteride (oral)0.02mg	8.188 (5.744, 10.65)	14.36 (12.03, 16.8)	6.76 (0.1094, 13.34)	7.29 (4.935, 9.521)	12.08 (6.014, 18.14)	6.53 (2.857, 10.1)	-9.294 (-23.57, 4.929)	-0.6186 (-11.62, 10.5)	-6.879 (-17.38, 3.547)	4.726 (-6.763, 16.36)	5.839 (1.991, 9.69)	-0.3856 (-7.514, 6.777)	11.07 (-1.389, 23.61)	-4.334 (-6.631, -2.011)
-8.188 (-10.65, -5.744)	dutasteride (oral)0.1mg	6.166 (3.842, 8.573)	-1.432 (-8.051, 5.139)	-0.9025 (-3.274, 1.309)	3.884 (-2.151, 9.926)	-1.668 (-5.374, 1.906)	-17.46 (-31.79, -3.2)	-8.806 (-19.9, 2.243)	-15.09 (-25.6, -4.638)	-3.48 (-14.96, 8.146)	-2.353 (-6.179, 1.497)	-8.558 (-15.68, -1.408)	2.861 (-9.639, 15.38)	-12.53 (-14.82, -10.2)
-14.36 (-16.8, -12.03)	-6.166 (-8.573, -3.842)	dutasteride (oral)0.5mg	-7.612 (-14.2, -1.102)	-7.095 (-9.283, -5.068)	-2.306 (-8.281, 3.681)	-7.844 (-11.47, -4.426)	-23.65 (-38.01, -9.457)	-15.02 (-26.07, -3.925)	-21.27 (-31.75, -10.86)	-9.644 (-21.18, 1.995)	-8.535 (-12.3, -4.8)	-14.75 (-21.88, -7.642)	-3.332 (-15.81, 9.198)	-18.7 (-20.86, -16.59)
-6.76 (-13.34, -0.1094)	1.432 (-5.139, 8.051)	7.612 (1.102, 14.2)	finasteride (oral)0.2mg	0.5022 (-5.792, 6.847)	5.324 (-3.113, 13.83)	-0.2529 (-7.179, 6.687)	-16.04 (-31.6, -0.5155)	-7.405 (-19.93, 5.041)	-13.65 (-25.69, -1.686)	-2.015 (-15.09, 10.97)	-0.9311 (-7.976, 6.192)	-7.144 (-16.41, 2.183)	4.294 (-9.523, 18.16)	-11.09 (-17.42, -4.695)
-7.29 (-9.521, -4.935)	0.9025 (-1.309, 3.274)	7.095 (5.068, 9.283)	-0.5022 (-6.847, 5.792)	finasteride (oral)1mg	4.809 (-1.075, 10.75)	-0.7557 (-3.564, 2.045)	-16.54 (-30.8, -2.348)	-7.886 (-18.92, 3.136)	-14.16 (-24.6, -3.818)	-2.546 (-13.99, 9.005)	-1.431 (-5.006, 2.211)	-7.643 (-14.67, -0.5837)	3.791 (-8.585, 16.3)	-11.61 (-13.42, -9.685)
-12.08 (-18.14, -6.014)	-3.884 (-9.926, 2.151)	2.306 (-3.681, 8.281)	-5.324 (-13.83, 3.113)	-4.809 (-10.75, 1.075)	finasteride (oral)5mg	-5.565 (-12.15, 0.9666)	-21.35 (-36.71, -6.108)	-12.7 (-24.88, -0.5349)	-18.98 (-30.65, -7.358)	-7.328 (-19.94, 5.268)	-6.234 (-12.63, 0.1395)	-12.46 (-21.24, -3.659)	-1.008 (-14.54, 12.53)	-16.4 (-22.01, -10.84)
-6.53 (-10.1, -2.857)	1.668 (-1.906, 5.374)	7.844 (4.426, 11.47)	0.2529 (-6.687, 7.179)	0.7557 (-2.045, 3.564)	5.565 (-0.9666, 12.15)	finasteride (topical)1%	-15.78 (-30.34, -1.3)	-7.131 (-18.51, 4.174)	-13.4 (-24.17, -2.668)	-1.779 (-13.56, 10.15)	-0.6898 (-5.188, 3.959)	-6.886 (-14.39, 0.76)	4.542 (-8.184, 17.42)	-10.85 (-14.17, -7.415)
9.294 (-4.929, 23.57)	17.46 (3.2, 31.79)	23.65 (9.457, 38.01)	16.04 (0.5155, 31.6)	16.54 (2.348, 30.8)	21.35 (6.108, 36.71)	15.78 (1.3, 30.34)	minoxidil (oral)0.25mg	8.697 (-9.231, 26.52)	2.377 (-15.19, 20.04)	14.04 (-4.251, 32.15)	15.13 (0.5178, 29.71)	8.951 (-6.819, 24.58)	20.38 (1.597, 39.13)	4.961 (-9.262, 19.21)
0.6186 (-10.5, 11.62)	8.806 (-2.243, 19.9)	15.02 (3.925, 26.07)	7.405 (-5.041, 19.93)	7.886 (-3.136, 18.92)	12.7 (0.5349, 24.88)	7.131 (-4.174, 18.51)	-8.697 (-26.52, 9.231)	minoxidil (oral)5mg	-6.305 (-20.82, 8.255)	5.345 (-10.01, 20.81)	6.469 (-3.929, 16.9)	0.2306 (-8.185, 8.743)	11.7 (-4.388, 27.83)	-3.684 (-14.56, 7.16)
6.879 (-3.547, 17.38)	15.09 (4.638, 25.6)	21.27 (10.86, 31.75)	13.65 (1.686, 25.69)	14.16 (3.818, 24.6)	18.98 (7.358, 30.65)	13.4 (2.668, 24.17)	-2.377 (-20.04, 15.19)	6.305 (-8.255, 20.82)	minoxidil (topical)0.1%	11.65 (-0.7225, 24.04)	12.75 (2.52, 23.1)	6.555 (-5.33, 18.49)	17.95 (4.75, 31.37)	2.576 (-7.566, 12.81)
-4.726 (-16.36, 6.763)	3.48 (-8.146, 14.96)	9.644 (-1.995, 21.18)	2.015 (-10.97, 15.09)	2.546 (-9.005, 13.99)	7.328 (-5.268, 19.94)	1.779 (-10.15, 13.56)	-14.04 (-32.15, 4.251)	-5.345 (-20.81, 10.01)	-11.65 (-24.04, 0.7225)	minoxidil (topical)1%	1.142 (-10.34, 12.5)	-5.077 (-18.02, 7.732)	6.32 (1.533, 11.05)	-9.029 (-20.44, 2.263)
-5.839 (-9.69, -1.991)	2.353 (-1.497, 6.179)	8.535 (4.8, 12.3)	0.9311 (-6.192, 7.976)	1.431 (-2.211, 5.006)	6.234 (-0.1395, 12.63)	0.6898 (-3.959, 5.188)	-15.13 (-29.71, -0.5178)	-6.469 (-16.9, 3.929)	-12.75 (-23.1, -2.52)	-1.142 (-12.5, 10.34)	minoxidil (topical)2%	-6.203 (-12.27, -0.1566)	5.2 (-7.096, 17.6)	-10.17 (-13.22, -7.088)
0.3856 (-6.777, 7.514)	8.558 (1.408, 15.68)	14.75 (7.642, 21.88)	7.144 (-2.183, 16.41)	7.643 (0.5837, 14.67)	12.46 (3.659, 21.24)	6.886 (-0.76, 14.39)	-8.951 (-24.58, 6.819)	-0.2306 (-8.743, 8.185)	-6.555 (-18.49, 5.33)	5.077 (-7.732, 18.02)	6.203 (0.1566, 12.27)	minoxidil (topical)3%	11.41 (-2.268, 25.21)	-3.946 (-10.77, 2.816)
-11.07 (-23.61, 1.389)	-2.861 (-15.38, 9.639)	3.332 (-9.198, 15.81)	-4.294 (-18.16, 9.523)	-3.791 (-16.3, 8.585)	1.008 (-12.53, 14.54)	-4.542 (-17.42, 8.184)	-20.38 (-39.13, -1.597)	-11.7 (-27.83, 4.388)	-17.95 (-31.37, -4.75)	-6.32 (-11.05, -1.533)	-5.2 (-17.6, 7.096)	-11.41 (-25.21, 2.268)	minoxidil (topical)5%	-15.38 (-27.75, -3.124)
4.334 (2.011, 6.631)	12.53 (10.2, 14.82)	18.7 (16.59, 20.86)	11.09 (4.695, 17.42)	11.61 (9.685, 13.42)	16.4 (10.84, 22.01)	10.85 (7.415, 14.17)	-4.961 (-19.21, 9.262)	3.684 (-7.16, 14.56)	-2.576 (-12.81, 7.566)	9.029 (-2.263, 20.44)	10.17 (7.088, 13.22)	3.946 (-2.816, 10.77)	15.38 (3.124, 27.75)	vehicle or placebo

eFigure 5. League table for our first endpoint (i.e., ‘outcome 1’). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 2%, is significantly more efficacious than vehicle or placebo (mean difference = 10.17, p<0.05).

finasteride (oral)1mg	-0.8689 (-3.583, 1.846)	-33.22 (-47.28, -19.11)	10.43 (2.203, 18.59)	-28.94 (-38.63, -19.19)	-23.73 (-33.07, -14.33)	-18.84 (-26.98, -10.67)	-19.37 (-29.54, -9.202)	-30.12 (-38.62, -21.57)
0.8689 (-1.846, 3.583)	finasteride (topical)1%	-32.35 (-46.63, -17.93)	11.29 (2.641, 19.94)	-28.06 (-38.13, -17.93)	-22.85 (-32.58, -13.1)	-17.98 (-26.56, -9.372)	-18.51 (-29.04, -8.001)	-29.25 (-38.15, -20.32)
33.22 (19.11, 47.28)	32.35 (17.93, 46.63)	minoxidil (oral)0.25mg	43.63 (29.65, 57.66)	4.282 (-10.49, 19.12)	9.516 (-5.081, 24.27)	14.39 (0.4595, 28.3)	13.84 (-1.273, 29.06)	3.112 (-10.98, 17.26)
-10.43 (-18.59, -2.203)	-11.29 (-19.94, -2.641)	-43.63 (-57.66, -29.65)	minoxidil (oral)5mg	-39.33 (-49.02, -29.66)	-34.14 (-43.41, -24.83)	-29.27 (-37.46, -21.1)	-29.78 (-39.83, -19.69)	-40.54 (-49.06, -32.09)
28.94 (19.19, 38.63)	28.06 (17.93, 38.13)	-4.282 (-19.12, 10.49)	39.33 (29.66, 49.02)	minoxidil (topical) 0.10%	5.202 (-0.466, 10.9)	10.09 (4.933, 15.27)	9.538 (2.666, 16.47)	-1.188 (-6.203, 3.811)
23.73 (14.33, 33.07)	22.85 (13.1, 32.58)	-9.516 (-24.27, 5.081)	34.14 (24.83, 43.41)	-5.202 (-10.9, 0.466)	minoxidil (topical)1%	4.888 (0.4283, 9.409)	4.348 (0.4302, 8.219)	-6.395 (-10.67, -2.116)
18.84 (10.67, 26.98)	17.98 (9.372, 26.56)	-14.39 (-28.3, -0.4595)	29.27 (21.1, 37.46)	-10.09 (-15.27, -4.933)	-4.888 (-9.409, -0.4283)	minoxidil (topical)2%	-0.5417 (-6.449, 5.356)	-11.28 (-13.68, -8.936)
19.37 (9.202, 29.54)	18.51 (8.001, 29.04)	-13.84 (-29.06, 1.273)	29.78 (19.69, 39.83)	-9.538 (-16.47, -2.666)	-4.348 (-8.219, -0.4302)	0.5417 (-5.356, 6.449)	minoxidil (topical)5%	-10.74 (-16.46, -4.993)
30.12 (21.57, 38.62)	29.25 (20.32, 38.15)	-3.112 (-17.26, 10.98)	40.54 (32.09, 49.06)	1.188 (-3.811, 6.203)	6.395 (2.116, 10.67)	11.28 (8.936, 13.68)	10.74 (4.993, 16.46)	vehicle or placebo


Figure 6. League table for our second endpoint (i.e., ‘outcome 2’). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 2%, is significantly more efficacious than vehicle or placebo (mean difference = 11.3, p<0.05).

finasteride(oral)1mg	5.176 (-1.579, 11.89)	-15.5 (-24.35, -6.55)	-19.02 (-30.95, -7.165)	-16.37 (-19.6, -13.17)
-5.176 (-11.89, 1.579)	finasteride(oral)5mg	-20.65 (-31.85, -9.516)	-24.2 (-37.86, -10.48)	-21.54 (-27.46, -15.58)
15.5 (6.55, 24.35)	20.65 (9.516, 31.85)	minoxidil(topical)2%	-3.538 (-11.34, 4.358)	-0.8918 (-10.39, 8.595)
19.02 (7.165, 30.95)	24.2 (10.48, 37.86)	3.538 (-4.358, 11.34)	minoxidil(topical)3%	2.657 (-9.745, 15.01)
16.37 (13.17, 19.6)	21.54 (15.58, 27.46)	0.8918 (-8.595, 10.39)	-2.657 (-15.01, 9.745)	vehicle or placebo

eFigure 7. League table for our third endpoint (i.e., ‘outcome 3’). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 48 weeks of therapy in men with androgenetic alopecia. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, finasteride (oral) 5mg, is significantly more efficacious than vehicle or placebo (mean difference = 21.54, p<0.05).

finasteride(oral)1mg	-32.07 (-40.32, -23.87)	-20.71 (-36.65, -4.554)	-26.19 (-36.21, -16.23)	-40.81 (-51.14, -30.39)
32.07 (23.87, 40.32)	minoxidil(topical)2%	11.4 (-2.227, 25.14)	5.885 (0.1603, 11.63)	-8.714 (-15.05, -2.371)
20.71 (4.554, 36.65)	-11.4 (-25.14, 2.227)	minoxidil(topical)3%	-5.486 (-20.43, 9.351)	-20.08 (-35.26, -5.09)
26.19 (16.23, 36.21)	-5.885 (-11.63, -0.1603)	5.486 (-9.351, 20.43)	minoxidil(topical)5%	-14.62 (-21.48, -7.793)
40.81 (30.39, 51.14)	8.714 (2.371, 15.05)	20.08 (5.09, 35.26)	14.62 (7.793, 21.48)	vehicle or placebo

eFigure 8. League table for our fourth endpoint (i.e., ‘outcome 4’). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 48 weeks of therapy in men with androgenetic alopecia. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 5% is significantly more efficacious than vehicle or placebo (mean difference = 14.62, p<0.05).



eFigure 9. Presentation of treatments’ surface under the cumulative ranking curve (SUCRA) via a modified Kilim plot for data from only randomized trials and both randomized and observational studies.

Names were prefixed with upper case alphabets solely for the purpose of ordering.

Left: a ‘color chart’ for SUCRA values; red and green (which are arbitrarily chosen colors) correspond to lowest and highest SUCRA values which, in turn, correspond to the least and the most effective treatment as per this ranking metric, respectively.

Right: A treatment’s SUCRA corresponds to its overall rank for efficacy (higher values corresponding to greater efficacy). The vertical and horizontal axes correspond to the treatments and the endpoints, respectively. The leftmost column and the one adjacent to it present SUCRA values for change in total hair count (in hairs/cm²) are 24 weeks; the latter (i.e., column titled ‘B_SUCRA_total_24weeks_RANDOM’) is solely based on randomized evidence, while the former is based on both observational and randomized data. The rightmost column and the one adjacent to it present SUCRA values for change in terminal hair count (in hairs/cm²) after 24 weeks; the latter (i.e., column titled ‘B_SUCRA_terminal_24weeks’) is based on both observational and randomized data randomized evidence, while the former solely based on randomized data.

dutasteride(oral)0.02mg	8.19 (5.72, 10.64)	14.35 (12.03, 16.8)	6.72 (0.13, 13.31)	7.27 (4.94, 9.53)	12.06 (6.04, 18.06)	6.52 (2.89, 10.07)	-7.2 (-17.46, 3.13)	4.22 (-7.28, 15.71)	5.85 (2.05, 9.68)	-0.43 (-7.5, 6.76)	10.55 (-1.87, 23.04)	-4.34 (-6.61, -2.02)
-8.19 (-10.64, -5.72)	dutasteride(oral)0.1mg	6.17 (3.82, 8.6)	-1.47 (-8.05, 5.07)	-0.91 (-3.28, 1.35)	3.87 (-2.16, 9.88)	-1.67 (-5.31, 1.91)	-15.41 (-25.67, -5.03)	-3.98 (-15.44, 7.52)	-2.33 (-6.15, 1.48)	-8.62 (-15.7, -1.42)	2.33 (-10.09, 14.85)	-12.53 (-14.84, -10.2)
-14.35 (-16.8, -12.03)	-6.17 (-8.6, -3.82)	dutasteride(oral)0.5mg	-7.65 (-14.21, -1.14)	-7.09 (-9.3, -5.07)	-2.3 (-8.32, 3.62)	-7.85 (-11.45, -4.42)	-21.61 (-31.82, -11.23)	-10.17 (-21.67, 1.32)	-8.51 (-12.25, -4.8)	21.84 (-7.67, 14.85)	-3.85 (-16.2, 8.64)	-18.69 (-20.88, -16.58)
-6.72 (-13.31, -0.13)	1.47 (-5.07, 8.05)	7.65 (1.14, 14.21)	finasteride(oral)0.2mg	0.53 (-5.79, 6.87)	5.34 (-3.1, 13.8)	-0.21 (-7.14, 6.68)	-13.92 (-25.73, -1.93)	15.36 (10.45, 20.45)	-0.86 (-7.84, 6.18)	-7.14 (-16.34, 2.15)	3.8 (-9.92, 17.63)	-11.04 (-17.36, -4.7)
-7.27 (-9.53, -4.94)	0.91 (-1.35, 3.28)	7.09 (5.07, 9.3)	-0.53 (-6.87, 5.79)	finasteride(oral)1mg	4.81 (-1.08, 10.65)	-0.75 (-3.55, 2.03)	-14.47 (-24.65, -4.21)	-3.06 (-14.46, 8.38)	-1.41 (-4.95, 2.21)	-7.68 (-14.64, -0.63)	3.27 (-9.06, 15.72)	-11.61 (-13.42, -9.68)
-12.06 (-18.06, -6.04)	-3.87 (-9.88, 2.16)	2.3 (-3.62, 8.32)	-5.34 (-13.8, 3.1)	-4.81 (-10.65, 1.08)	finasteride(oral)5mg	-5.56 (-12.02, 0.97)	-19.29 (-30.79, -7.61)	-7.84 (-20.36, 4.76)	-6.21 (-12.5, 0.16)	21.22 (-3.69, 14.43)	11.91 (4.03, 16.76)	21.94 (-10.79, -10.85)
-6.52 (-10.07, -2.89)	1.67 (-1.91, 5.31)	7.85 (4.42, 11.45)	0.21 (-6.68, 7.14)	0.75 (-2.03, 3.55)	5.56 (-0.97, 12.02)	finasteride(topical)1%	-13.71 (-24.25, -3.04)	-2.3 (-9.45, 9.45)	-0.66 (-5.16, 3.93)	-6.93 (-14.43, 0.63)	4.03 (-8.65, 16.76)	-10.85 (-14.16, -7.44)
7.2 (-3.13, 17.46)	15.41 (5.03, 25.67)	21.61 (11.23, 31.82)	13.92 (1.93, 25.73)	14.47 (4.21, 24.65)	19.29 (7.61, 30.79)	13.71 (3.04, 24.25)	minoxidil(topical)0.1%	11.43 (-0.93, 23.72)	13.08 (2.89, 23.21)	6.8 (-4.92, 18.62)	17.74 (4.48, 30.97)	2.88 (-7.28, 12.91)
-4.22 (-15.71, 7.28)	3.98 (-7.52, 15.44)	10.17 (-1.32, 21.67)	2.52 (-10.45, 15.36)	3.06 (-8.38, 14.46)	7.84 (-4.76, 20.36)	2.3 (-9.45, 14.04)	-11.43 (-23.72, 0.93)	minoxidil(topical)1%	1.65 (-9.6, 13.03)	-4.63 (-17.36, 8.21)	6.34 (1.53, 11.12)	-8.54 (-19.88, 2.7)
-5.85 (-9.68, -2.05)	2.33 (-1.48, 6.15)	8.51 (4.8, 12.25)	0.86 (-6.18, 7.84)	1.41 (-2.21, 4.95)	6.21 (-0.16, 12.5)	0.66 (-3.93, 5.16)	-13.08 (-23.21, -2.89)	-1.65 (-13.03, 9.6)	minoxidil(topical)2%	-6.27 (-12.28, -0.26)	4.68 (-7.68, 16.96)	-10.19 (-13.26, -7.13)
0.43 (-6.76, 7.5)	8.62 (1.42, 15.7)	14.8 (7.67, 21.84)	7.14 (-2.15, 16.34)	7.68 (0.63, 14.64)	12.5 (3.69, 21.22)	6.93 (-0.63, 14.43)	-6.8 (-18.62, 4.92)	4.63 (-8.21, 17.36)	6.27 (0.26, 12.28)	minoxidil(topical)3%	10.96 (-2.76, 24.62)	-3.92 (-10.72, 2.82)
-10.55 (-23.04, 1.87)	-2.33 (-14.85, 10.09)	3.85 (-8.64, 16.2)	-3.8 (-17.63, 9.92)	-3.27 (-15.72, 9.06)	11.91 (14.91, 14.91)	-4.03 (-11.91, 16.76)	-17.74 (-30.97, -4.48)	-6.34 (-11.12, -1.53)	-4.68 (-16.96, 7.68)	-10.96 (-24.62, 2.76)	minoxidil(topical)5%	-14.84 (-27.12, -2.65)
4.34 (2.02, 6.61)	12.53 (10.2, 14.84)	18.69 (16.58, 20.88)	11.04 (4.7, 17.36)	11.61 (9.68, 13.42)	16.4 (10.79, 21.94)	10.85 (7.44, 14.16)	-2.88 (-12.91, 7.28)	8.54 (-2.7, 19.88)	10.19 (7.13, 13.26)	3.92 (-2.82, 10.72)	14.84 (2.65, 27.12)	vehicle or placebo

eFigure 10. League table for our first endpoint (i.e., ‘outcome 1’) based on solely on data from randomized studies. This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 2%, is significantly more efficacious than vehicle or placebo (mean difference = 10.19, p<0.05).

finasteride(oral)1mg	-0.88 (-3.57, 1.82)	-29.02 (-38.61, -19.29)	-23.75 (-33.08, -14.38)	-18.87 (-27, -10.64)	-19.43 (-29.52, -9.28)	-30.14 (-38.62, -21.55)
0.88 (-1.82, 3.57)	finasteride(topical)1%	-28.14 (-38.11, -18.04)	-22.89 (-32.6, -13.13)	-17.99 (-26.57, -9.32)	-18.54 (-28.96, -8.09)	-29.26 (-38.15, -20.28)
29.02 (19.29, 38.61)	28.14 (18.04, 38.11)	minoxidil(topical)0.1%	5.26 (-0.48, 10.89)	10.15 (4.93, 15.22)	9.57 (2.63, 16.46)	-1.13 (-6.2, 3.8)
23.75 (14.38, 33.08)	22.89 (13.13, 32.6)	-5.26 (-10.89, 0.48)	minoxidil(topical)1%	4.89 (0.42, 9.32)	4.34 (0.43, 8.26)	-6.37 (-10.68, -2.14)
18.87 (10.64, 27)	17.99 (9.32, 26.57)	-10.15 (-15.22, -4.93)	-4.89 (-9.32, -0.42)	minoxidil(topical)2%	-0.56 (-6.45, 5.34)	-11.26 (-13.64, -8.91)
19.43 (9.28, 29.52)	18.54 (8.09, 28.96)	-9.57 (-16.46, -2.63)	-4.34 (-8.26, -0.43)	0.56 (-5.34, 6.45)	minoxidil(topical)5%	-10.71 (-16.55, -4.94)
30.14 (21.55, 38.62)	29.26 (20.28, 38.15)	1.13 (-3.8, 6.2)	6.37 (2.14, 10.68)	11.26 (8.91, 13.64)	10.71 (4.94, 16.55)	vehicle or placebo

eFigure 11. League table for our second endpoint (i.e., ‘outcome 2’) based on solely on data from randomized studies. This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 2%, is significantly more efficacious than vehicle or placebo (mean difference = 11.26, p<0.05).





Figure 12. Presentation of treatments’ surface under the cumulative ranking curve (SUCRA) via a modified Kilim plot for ‘outcome 1’ in patients with: (1) any level of severity, (2) mild form of the condition, (3) moderate form of the condition, and (4) severe form of the condition.

Names were prefixed with upper case alphabets solely for the purpose of ordering. The condition of interest is male androgenetic alopecia (AGA), and ‘outcome 1’ corresponded to change in total hair count at 24 weeks. Left: a ‘color chart’ for SUCRA values; red and green (which are arbitrarily chosen colors) correspond to lowest and highest SUCRA values which, in turn, correspond to the least and the most effective treatment as per this ranking metric, respectively. Right: A treatment’s SUCRA corresponds to its overall rank for efficacy (higher values corresponding to greater efficacy). The vertical and horizontal axes correspond to the treatments and the endpoints, respectively.


The leftmost column corresponds to SUCRA values based on study subjects with any level of severity; the subsequent columns correspond to subjects who exclusively had mild, moderate and severe, respectively. mild, moderate and severe androgenetic alopecia mainly referred to the Hamilton-Norwood (1) I – II, (2) III – IV, and (3) V or above, respectively.



eFigure 13. Presentation of treatments’ surface under the cumulative ranking curve (SUCRA) via a modified Kilim plot for ‘outcome 2’ in patients with: (1) any level of severity, (2) mild form of the condition, (3) moderate form of the condition, and (4) severe form of the condition.

Names were prefixed with upper case alphabets solely for the purpose of ordering. The condition of interest is male androgenetic alopecia (AGA), and ‘outcome 2’ corresponded to change in terminal hair count at 24 weeks. Left: a ‘color chart’ for SUCRA values; red and green (which are arbitrarily chosen colors) correspond to lowest and highest SUCRA values which, in turn, correspond to the least and the most effective treatment as per this ranking metric, respectively. Right: A treatment’s SUCRA corresponds to its overall rank for efficacy (higher values corresponding to greater efficacy). The vertical and horizontal axes correspond to the treatments and the endpoints, respectively.


The leftmost column corresponds to SUCRA values based on study subjects with any level of severity; the subsequent columns correspond to subjects who exclusively had mild, moderate and severe, respectively. mild, moderate and severe androgenetic alopecia mainly referred to the Hamilton-Norwood (1) I – II, (2) III – IV, and (3) V or above, respectively.



eFigure 14. Presentation of treatments’ surface under the cumulative ranking curve (SUCRA) via a modified Kilim plot for ‘outcome 3’ in patients with: (1) any level of severity, (2) mild form of the condition, (3) moderate form of the condition, and (4) severe form of the condition.

Names were prefixed with upper case alphabets solely for the purpose of ordering. The condition of interest is male androgenetic alopecia (AGA), and ‘outcome 3’ corresponded to change in total hair count at 48 weeks. Left: a ‘color chart’ for SUCRA values; red and green (which are arbitrarily chosen colors) correspond to lowest and highest SUCRA values which, in turn, correspond to the least and the most effective treatment as per this ranking metric, respectively. Right: A treatment’s SUCRA corresponds to its overall rank for efficacy (higher values corresponding to greater efficacy). The vertical and horizontal axes correspond to the treatments and the endpoints, respectively.

The leftmost column corresponds to SUCRA values based on study subjects with any level of severity; the subsequent columns correspond to subjects who exclusively had mild, moderate and severe, respectively. mild, moderate and severe androgenetic alopecia mainly referred to the Hamilton-Norwood (1) I – II, (2) III – IV, and (3) V or above, respectively.



eFigure 15. Presentation of treatments’ surface under the cumulative ranking curve (SUCRA) via a modified Kilim plot for ‘outcome 4’ in patients with: (1) any level of severity, (2) mild form of the condition, (3) moderate form of the condition, and (4) severe form of the condition.

Names were prefixed with upper case alphabets solely for the purpose of ordering. The condition of interest is male androgenetic alopecia (AGA), and ‘outcome 4’ corresponded to change in terminal hair count at 48 weeks. Left: a ‘color chart’ for SUCRA values; red and green (which are arbitrarily chosen colors) correspond to lowest and highest SUCRA values which, in turn, correspond to the least and the most effective treatment as per this ranking metric, respectively. Right: A treatment’s SUCRA corresponds to its overall rank for efficacy (higher values corresponding to greater efficacy). The vertical and horizontal axes correspond to the treatments and the endpoints, respectively.

The leftmost column corresponds to SUCRA values based on study subjects with any level of severity; the subsequent columns correspond to subjects who exclusively had mild, moderate and severe, respectively. mild, moderate and severe androgenetic alopecia mainly referred to the Hamilton-Norwood (1) I – II, (2) III – IV, and (3) V or above, respectively.

dutasteride(oral)0.02mg	8.19 (5.72, 10.67)	14.36 (12.03, 16.79)	6.76 (0.13, 13.38)	7.32 (4.92, 9.58)	12.08 (6.1, 18.06)	-9.38 (-23.64, 5.23)	5 (-3.08, 12.98)	-7.04 (-17.45, 3.47)	3.98 (-7.19, 15.03)	5.84 (2.03, 9.72)	10.37 (-1.8, 22.36)	-3.63 (-12.32, 5.41)
-8.19 (-10.67, -5.72)	dutasteride(oral)0.1mg	6.17 (3.85, 8.61)	-1.42 (-8.02, 5.21)	-0.87 (-3.25, 1.4)	3.87 (-2.12, 9.91)	-17.58 (-31.79, -2.94)	-3.2 (-11.2, 4.79)	-15.23 (-25.63, -4.73)	-4.19 (-15.31, 6.77)	-2.35 (-6.16, 1.54)	2.15 (-9.94, 14.1)	-11.84 (-20.39, -2.76)
-14.36 (-16.79, -12.03)	-6.17 (-8.61, -3.85)	dutasteride(oral)0.5mg	-7.62 (-14.21, -1.08)	-7.06 (-9.29, -4.99)	-2.31 (-8.28, 3.66)	-23.77 (-38.03, -9.19)	-9.39 (-17.39, -1.42)	-21.42 (-31.81, -10.96)	-10.38 (-21.53, 0.61)	-8.54 (-12.3, -4.77)	-4.01 (-16.11, 7.9)	-18.02 (-26.6, -9.01)
-6.76 (-13.38, -0.13)	1.42 (-5.21, 8.02)	7.62 (1.08, 14.21)	finasteride(oral)0.2mg	0.55 (-5.81, 6.87)	5.32 (-3.23, 13.76)	-16.16 (-31.76, -0.32)	-1.79 (-11.77, 8.13)	-13.78 (-25.85, -1.8)	-2.79 (-15.43, 9.68)	-0.91 (-7.97, 6.14)	3.58 (-9.9, 16.99)	-10.38 (-20.76, 0.39)
-7.32 (-9.58, -4.92)	0.87 (-1.4, 3.25)	7.06 (4.99, 9.29)	-0.55 (-6.87, 5.81)	finasteride(oral)1mg	4.77 (-1.11, 10.7)	-16.68 (-30.89, -2.09)	-2.31 (-10.26, 5.59)	-14.34 (-24.67, -3.88)	-3.3 (-14.42, 7.65)	-1.47 (-5.1, 2.25)	3.06 (-9.04, 15)	-10.95 (-19.08, -2.3)
-12.08 (-18.06, -6.1)	-3.87 (-9.91, 2.12)	2.31 (-3.66, 8.28)	-5.32 (-13.76, 3.23)	-4.77 (-10.7, 1.11)	finasteride(oral)5mg	-21.47 (-36.77, -6.02)	-7.1 (-16.59, 2.34)	-19.08 (-30.77, -7.37)	-8.07 (-20.36, 3.97)	-6.22 (-12.6, 0.11)	-1.73 (-14.87, 11.32)	-15.69 (-25.98, -5.07)
9.38 (-5.23, 23.64)	17.58 (2.94, 31.79)	23.77 (9.19, 38.03)	16.16 (0.32, 31.76)	16.68 (2.09, 30.89)	21.47 (6.02, 36.77)	minoxidil(oral)0.25mg	14.4 (-2.13, 30.59)	2.39 (-15.44, 19.87)	13.32 (-4.82, 31.31)	15.26 (0.33, 29.8)	19.66 (0.92, 38.32)	5.84 (-10.85, 22.36)
-5 (-12.98, 3.08)	3.2 (-4.79, 11.2)	9.39 (1.42, 17.39)	1.79 (-8.13, 11.77)	2.31 (-5.59, 10.26)	7.1 (-2.34, 16.59)	-14.4 (-30.59, 2.13)	minoxidil(oral)5mg	-12.01 (-24.59, 0.64)	-1 (-14.06, 12.08)	0.87 (-6.73, 8.39)	5.37 (-8.52, 19.15)	-8.57 (-20.17, 3.31)
7.04 (-3.47, 17.45)	15.23 (4.73, 25.63)	21.42 (10.96, 31.81)	13.78 (1.8, 25.85)	14.34 (3.88, 24.67)	19.08 (7.37, 30.77)	-2.39 (-19.87, 15.44)	12.01 (-0.64, 24.59)	minoxidil(topical)0.1%	11.02 (-0.97, 22.98)	12.87 (2.55, 23.14)	17.37 (4.43, 30.16)	3.44 (-9.91, 16.98)
-3.98 (-15.03, 7.19)	4.19 (-6.77, 15.31)	10.38 (-0.61, 21.53)	2.79 (-9.68, 15.43)	3.3 (-7.65, 14.42)	8.07 (-3.97, 20.36)	-13.32 (-31.31, 4.82)	1 (-12.08, 14.06)	-11.02 (-22.98, 0.97)	minoxidil(topical)1%	1.82 (-8.96, 12.83)	6.33 (1.55, 11.12)	-7.61 (-21.38, 6.43)
-5.84 (-9.72, -2.03)	2.35 (-1.54, 6.16)	8.54 (4.77, 12.3)	0.91 (-6.14, 7.97)	1.47 (-2.25, 5.1)	6.22 (-0.11, 12.6)	-15.26 (-29.8, -0.33)	-0.87 (-8.39, 6.73)	-12.87 (-23.14, -2.55)	-1.82 (-12.83, 8.96)	minoxidil(topical)2%	4.51 (-7.49, 16.31)	-9.49 (-18.72, 0.14)
-10.37 (-22.36, 1.8)	-2.15 (-14.1, 9.94)	4.01 (-7.9, 16.11)	-3.58 (-16.99, 9.9)	-3.06 (-15, 9.04)	1.73 (-11.32, 14.87)	-19.66 (-38.32, -0.92)	-5.37 (-19.15, 8.52)	-17.37 (-30.16, -4.43)	-6.33 (-11.12, -1.55)	-4.51 (-16.31, 7.49)	minoxidil(topical)5%	-13.95 (-28.5, 0.91)
3.63 (-5.41, 12.32)	11.84 (2.76, 20.39)	18.02 (9.01, 26.6)	10.38 (-0.39, 20.76)	10.95 (2.3, 19.08)	15.69 (5.07, 25.98)	-5.84 (-22.36, 10.85)	8.57 (-3.31, 20.17)	-3.44 (-16.98, 9.91)	7.61 (-6.43, 21.38)	9.49 (-0.14, 18.72)	13.95 (-0.91, 28.5)	vehicle or placebo

eFigure 16. League table for our first endpoint (i.e., ‘outcome 1’)(for androgenetic alopecia that is MILD). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia **that is MILD**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, finasteride(oral) 1mg, is significantly more efficacious than vehicle or placebo (mean difference = 10.95, p<0.05).

dutasteride(oral)0.02mg	8.2 (5.76, 10.64)	14.37 (12.07, 16.78)	6.02 (-0.67, 12.76)	7.43 (5.07, 9.66)	10.26 (3.65, 16.83)	-9.33 (-23.69, 4.95)	4.51 (-3.5, 12.44)	-8.65 (-19.43, 1.96)	2.36 (-9.01, 13.71)	4.73 (0.53, 8.88)	8.67 (-3.67, 21.02)	-6.13 (-9.91, -2.81)
-8.2 (-10.64, -5.76)	dutasteride(oral)0.1mg	6.17 (3.86, 8.59)	-2.15 (-8.89, 4.52)	-0.77 (-3.11, 1.46)	2.06 (-4.55, 8.59)	-17.52 (-31.96, -3.25)	-3.68 (-11.69, 4.25)	-16.82 (-27.57, -6.25)	-5.84 (-17.24, 5.56)	-3.48 (-7.67, 0.67)	0.49 (-11.85, 12.8)	-14.33 (-18.11, -10.99)
-14.37 (-16.78, -12.07)	-6.17 (-8.59, -3.86)	dutasteride(oral)0.5mg	-8.36 (-15.05, -1.71)	-6.95 (-9.16, -4.94)	-4.12 (-10.7, 2.36)	-23.72 (-38.08, -9.5)	-9.87 (-17.84, -1.95)	-23.05 (-33.77, -12.43)	-12.03 (-23.39, -0.71)	-9.66 (-13.83, -5.61)	-5.72 (-18.04, 6.59)	-20.5 (-24.25, -17.3)
-6.02 (-12.76, 0.67)	2.15 (-4.52, 8.89)	8.36 (1.71, 15.05)	finasteride(oral)0.2mg	1.37 (-5.13, 7.87)	4.23 (-4.37, 12.82)	-15.43 (-30.96, 0.18)	-1.53 (-11.44, 8.35)	-14.67 (-26.75, -2.68)	-3.68 (-16.33, 9.11)	-1.31 (-8.4, 5.7)	2.64 (-10.89, 16.31)	-12.22 (-18.74, -5.69)
-7.43 (-9.66, -5.07)	0.77 (-1.46, 3.11)	6.95 (4.94, 9.16)	-1.37 (-7.87, 5.13)	finasteride(oral)1mg	2.85 (-3.74, 9.35)	-16.73 (-31.11, -2.49)	-2.9 (-10.78, 4.93)	-16.04 (-26.78, -5.44)	-5.04 (-16.39, 6.25)	-2.68 (-6.77, 1.35)	1.27 (-11.04, 13.57)	-13.52 (-17.24, -10.37)
-10.26 (-16.83, -3.65)	-2.06 (-8.59, 4.55)	4.12 (-2.36, 10.7)	-4.23 (-12.82, 4.37)	-2.85 (-9.35, 3.74)	finasteride(oral)5mg	-19.66 (-35.16, -4.06)	-5.74 (-15.43, 3.85)	-18.92 (-30.59, -7.31)	-7.9 (-20.07, 4.38)	-5.52 (-11.95, 0.86)	-1.57 (-14.6, 11.61)	-16.44 (-21.98, -10.9)
9.33 (-4.95, 23.69)	17.52 (3.25, 31.96)	23.72 (9.5, 38.08)	15.43 (-0.18, 30.96)	16.73 (2.49, 31.11)	19.66 (4.06, 35.16)	minoxidil(oral)0.25mg	13.89 (-2.36, 30.03)	0.79 (-16.91, 18.22)	11.73 (-6.36, 29.99)	14.07 (-0.58, 28.76)	18.05 (-0.59, 36.93)	3.16 (-11.4, 17.68)
-4.51 (-12.44, 3.5)	3.68 (-4.25, 11.69)	9.87 (1.95, 17.84)	1.53 (-8.35, 11.44)	2.9 (-4.93, 10.78)	5.74 (-3.85, 15.43)	-13.89 (-30.03, 2.36)	minoxidil(oral)5mg	-13.16 (-25.79, -0.44)	-2.15 (-15.33, 11.05)	0.2 (-7.27, 7.84)	4.19 (-9.84, 18.29)	-10.7 (-18.51, -2.78)
8.65 (-1.96, 19.43)	16.82 (6.25, 27.57)	23.05 (12.43, 33.77)	14.67 (2.68, 26.75)	16.04 (5.44, 26.78)	18.92 (7.31, 30.59)	-0.79 (-18.22, 16.91)	13.16 (0.44, 25.79)	minoxidil(topical)0.1%	11.08 (-1.08, 22.91)	13.37 (3.08, 23.71)	17.38 (4.33, 30.27)	2.46 (-7.74, 12.76)
-2.36 (-13.71, 9.01)	5.84 (-5.56, 17.24)	12.03 (0.71, 23.39)	3.68 (-9.11, 16.33)	5.04 (-6.25, 16.39)	7.9 (-4.38, 20.07)	-11.73 (-29.99, 6.36)	2.15 (-11.05, 15.33)	-11.08 (-22.91, 1.08)	minoxidil(topical)1%	2.34 (-8.54, 13.33)	6.33 (1.53, 11.11)	-8.56 (-19.43, 2.28)
-4.73 (-8.88, -0.53)	3.48 (-0.67, 7.67)	9.66 (5.61, 13.83)	1.31 (-5.7, 8.4)	2.68 (-1.35, 6.77)	5.52 (-0.86, 11.95)	-14.07 (-28.76, 0.58)	-0.2 (-7.84, 7.27)	-13.37 (-23.71, -3.08)	-2.34 (-13.33, 8.54)	minoxidil(topical)2%	3.99 (-7.96, 15.89)	-10.91 (-14.16, -7.69)
-8.67 (-21.02, 3.67)	-0.49 (-12.8, 11.85)	5.72 (-6.59, 18.04)	-2.64 (-16.31, 10.89)	-1.27 (-13.57, 11.04)	1.57 (-11.61, 14.6)	-18.05 (-36.93, 0.59)	-4.19 (-18.29, 9.84)	-17.38 (-30.27, -4.33)	-6.33 (-11.11, -1.53)	-3.99 (-15.89, 7.96)	minoxidil(topical)5%	-14.86 (-26.79, -2.99)
6.13 (2.81, 9.91)	14.33 (10.99, 18.11)	20.5 (17.3, 24.25)	12.22 (5.69, 18.74)	13.52 (10.37, 17.24)	16.44 (10.9, 21.98)	-3.16 (-17.68, 11.4)	10.7 (2.78, 18.51)	-2.46 (-12.76, 7.74)	8.56 (-2.28, 19.43)	10.91 (7.69, 14.16)	14.86 (2.99, 26.79)	vehicle or placebo

eFigure 17. League table for our first endpoint (i.e., ‘outcome 1’) (for androgenetic alopecia that is MODERATE). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia that is MODERATE. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 2%, is significantly more efficacious than vehicle or placebo (mean difference = 10.91, p<0.05).

dutasteride(oral)0.02mg	8.2 (5.73, 10.66)	14.37 (12.06, 16.8)	5.79 (-0.98, 12.5)	7.11 (4.7, 9.36)	10.23 (3.66, 16.75)	-9.35 (-23.63, 4.96)	4.73 (-3.26, 12.69)	-8.61 (-19.45, 2.2)	2.75 (-8.87, 14.03)	4.86 (0.75, 8.93)	9.06 (-3.59, 21.35)	1.94 (-6.4, 12.75)
-8.2 (-10.66, -5.73)	dutasteride(oral)0.1mg	6.18 (3.84, 8.64)	-2.4 (-9.21, 4.29)	-1.09 (-3.5, 1.17)	2.04 (-4.57, 8.57)	-17.54 (-31.8, -3.21)	-3.49 (-11.44, 4.51)	-16.79 (-27.61, -6.07)	-5.45 (-17.1, 5.87)	-3.34 (-7.48, 0.7)	0.84 (-11.8, 13.21)	-6.25 (-14.6, 4.59)
-14.37 (-16.8, -12.06)	-6.18 (-8.64, -3.84)	dutasteride(oral)0.5mg	-8.6 (-15.35, -1.9)	-7.29 (-9.52, -5.22)	-4.16 (-10.71, 2.3)	-23.74 (-38, -9.45)	-9.68 (-17.6, -1.76)	-22.98 (-33.81, -12.27)	-11.65 (-23.26, -0.34)	-9.53 (-13.6, 5.56)	-5.33 (-18, 7.03)	-12.44 (-20.71, -1.73)
-5.79 (-12.5, 0.98)	2.4 (-4.29, 9.21)	8.6 (1.9, 15.35)	finasteride(oral)0.2mg	1.29 (-5.15, 7.75)	4.44 (-4.09, 12.99)	-15.13 (-30.71, 0.39)	-1.06 (-11.14, 9.05)	-14.39 (-26.41, -2.3)	-3.06 (-16.02, 9.53)	-0.92 (-7.97, 6.17)	3.28 (-10.56, 16.77)	-3.79 (-15.27, 9.77)
-7.11 (-9.36, -4.7)	1.09 (-1.17, 3.5)	7.29 (5.22, 9.52)	-1.29 (-7.75, 5.15)	finasteride(oral)1mg	3.14 (-3.18, 9.46)	-16.44 (-30.73, -2.14)	-2.36 (-10.24, 5.52)	-15.66 (-26.4, -5.03)	-4.34 (-15.85, 6.83)	-2.23 (-6.04, 1.6)	1.98 (-10.54, 14.21)	-5.16 (-13.6, 5.91)
-10.23 (-16.75, -3.66)	-2.04 (-8.57, 4.57)	4.16 (-2.3, 10.71)	-4.44 (-12.99, 4.09)	-3.14 (-9.46, 3.18)	finasteride(oral)5mg	-19.58 (-35.08, -4.08)	-5.51 (-15.21, 4.31)	-18.82 (-30.58, -7.07)	-7.51 (-20.05, 4.77)	-5.36 (-11.82, 1.11)	-1.18 (-14.6, 12.05)	-8.3 (-20.14, 6.12)
9.35 (-4.96, 23.63)	17.54 (3.21, 31.8)	23.74 (9.45, 38)	15.13 (-0.39, 30.71)	16.44 (2.14, 30.73)	19.58 (4.08, 35.08)	minoxidil(oral)0.25mg	14.11 (-2.06, 30.25)	0.74 (-16.95, 18.43)	12.07 (-5.88, 29.96)	14.21 (-0.42, 28.87)	18.36 (-0.27, 36.85)	11.54 (-5.3, 28.93)
-4.73 (-12.69, 3.26)	3.49 (-4.51, 11.44)	9.68 (1.76, 17.6)	1.06 (-9.05, 11.14)	2.36 (-5.52, 10.24)	5.51 (-4.31, 15.21)	-14.11 (-30.25, 2.06)	minoxidil(oral)5mg	-13.29 (-26.05, -0.6)	-1.97 (-15.55, 11.2)	0.14 (-7.46, 7.74)	4.37 (-9.96, 18.42)	-2.64 (-14.24, 10.4)
8.61 (-2.2, 19.45)	16.79 (6.07, 27.61)	22.98 (12.27, 33.81)	14.39 (2.3, 26.41)	15.66 (5.03, 26.4)	18.82 (7.07, 30.58)	-0.74 (-18.43, 16.95)	13.29 (0.6, 26.05)	minoxidil(topical)0.1%	11.29 (-0.84, 23.38)	13.45 (3.05, 23.88)	17.64 (4.52, 30.62)	10.67 (-3.99, 26.87)
-2.75 (-14.03, 8.87)	5.45 (-5.87, 17.1)	11.65 (0.34, 23.26)	3.06 (-9.53, 16.02)	4.34 (-6.83, 15.85)	7.51 (-4.77, 20.05)	-12.07 (-29.96, 5.88)	1.97 (-11.2, 15.55)	-11.29 (-23.38, 0.84)	minoxidil(topical)1%	2.12 (-8.81, 13.48)	6.32 (1.58, 11.14)	-0.61 (-15.63, 15.92)
-4.86 (-8.93, -0.75)	3.34 (-0.7, 7.48)	9.53 (5.56, 13.6)	0.92 (-6.17, 7.97)	2.23 (-1.6, 6.04)	5.36 (-1.11, 11.82)	-14.21 (-28.87, 0.42)	-0.14 (-7.74, 7.46)	-13.45 (-23.88, -3.05)	-2.12 (-13.48, 8.81)	minoxidil(topical)2%	4.2 (-8.08, 16.19)	-2.96 (-12.77, 9.51)
-9.06 (-21.35, 3.59)	-0.84 (-13.21, 11.8)	5.33 (-7.03, 18)	-3.28 (-16.77, 10.56)	-1.98 (-14.21, 10.54)	1.18 (-12.05, 14.6)	-18.36 (-36.85, 0.27)	-4.37 (-18.42, 9.96)	-17.64 (-30.62, -4.52)	-6.32 (-11.14, -1.58)	minoxidil(topical)5%	-4.2 (-16.19, 8.08)	-6.94 (-22.79, 10.3)
-1.94 (-12.75, 6.4)	6.25 (-4.59, 14.6)	12.44 (1.73, 20.71)	3.79 (-9.77, 15.27)	5.16 (-5.91, 13.6)	8.3 (-6.12, 20.14)	-11.54 (-28.93, 5.3)	2.64 (-10.4, 14.24)	-10.67 (-26.87, 3.99)	0.61 (-15.92, 15.63)	2.96 (-9.51, 12.77)	6.94 (-10.3, 22.79)	vehicle or placebo

eFigure 18. League table for our first endpoint (i.e., ‘outcome 1’) (for androgenetic alopecia that is SEVERE). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia **that is SEVERE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, dutasteride(oral)0.5mg is significantly more efficacious than vehicle or placebo (mean difference = 12.44, p<0.05).

finasteride(oral)1mg	-33.09 (-47.27, -19.13)	10.49 (2.27, 18.69)	-28.91 (-38.5, -19.24)	-23.68 (-32.92, -14.45)	-18.74 (-26.92, -10.68)	-19.35 (-29.4, -9.32)	-30.14 (-131.77, 58.93)
33.09 (19.13, 47.27)	minoxidil(oral)0.25mg	43.57 (29.52, 57.68)	4.2 (-10.66, 19.19)	9.4 (-5.19, 23.99)	14.34 (0.47, 28.3)	13.77 (-1.39, 28.82)	3.03 (-97.75, 91.89)
-10.49 (-18.69, -2.27)	-43.57 (-57.68, -29.52)	minoxidil(oral)5mg	-39.39 (-48.98, -29.77)	-34.19 (-43.49, -24.94)	-29.23 (-37.41, -21.12)	-29.82 (-39.93, -19.77)	-40.62 (-141.91, 47.97)
28.91 (19.24, 38.5)	-4.2 (-19.19, 10.66)	39.39 (29.77, 48.98)	minoxidil(topical)0.1%	5.2 (-0.49, 10.83)	10.14 (5.01, 15.28)	9.56 (2.69, 16.41)	-1.25 (-102.59, 87.58)
23.68 (14.45, 32.92)	-9.4 (-23.99, 5.19)	34.19 (24.94, 43.49)	-5.2 (-10.83, 0.49)	minoxidil(topical)1%	4.96 (0.51, 9.41)	4.37 (0.43, 8.28)	-6.39 (-107.3, 82.22)
18.74 (10.68, 26.92)	-14.34 (-28.3, -0.47)	29.23 (21.12, 37.41)	-10.14 (-15.28, -5.01)	-4.96 (-9.41, -0.51)	minoxidil(topical)2%	-0.59 (-6.52, 5.26)	-11.37 (-112.62, 77.2)
19.35 (9.32, 29.4)	-13.77 (-28.82, 1.39)	29.82 (19.77, 39.93)	-9.56 (-16.41, -2.69)	-4.37 (-8.28, -0.43)	0.59 (-5.26, 6.52)	minoxidil(topical)5%	-10.8 (-111.69, 77.69)
30.14 (-58.93, 131.77)	-3.03 (-91.89, 97.75)	40.62 (-47.97, 141.91)	1.25 (-87.58, 102.59)	6.39 (-82.22, 107.3)	11.37 (-77.2, 112.62)	10.8 (-77.69, 111.69)	vehicle or placebo

eFigure 19. League table for our second endpoint (i.e., ‘outcome 2’) (for androgenetic alopecia that is MILD). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia **that is MILD**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 5%, is significantly more efficacious than minoxidil (topical)1% (mean difference = 4.37, p<0.05).

finasteride(oral)1mg	-33.14 (-47.08, -19.14)	10.44 (2.27, 18.69)	-29.51 (-39.22, -19.93)	-24.32 (-33.58, -15.05)	-18.79 (-26.94, -10.63)	-19.98 (-30.05, -9.88)	-30.94 (-39.49, -22.38)
33.14 (19.14, 47.08)	minoxidil(oral)0.25mg	43.63 (29.54, 57.53)	3.63 (-11.31, 18.3)	8.86 (-5.9, 23.22)	14.4 (0.42, 28.07)	13.22 (-2.08, 28.14)	2.25 (-12.03, 16.22)
-10.44 (-18.69, -2.27)	-43.63 (-57.53, -29.54)	minoxidil(oral)5mg	-39.99 (-49.59, -30.38)	-34.76 (-44.1, -25.56)	-29.25 (-37.33, -21.16)	-30.4 (-40.47, -20.44)	-41.37 (-49.95, -32.9)
29.51 (19.93, 39.22)	-3.63 (-18.3, 11.31)	39.99 (30.38, 49.59)	minoxidil(topical)0.1%	5.21 (-0.42, 10.89)	10.74 (5.6, 15.96)	9.57 (2.72, 16.44)	-1.41 (-6.32, 3.58)
24.32 (15.05, 33.58)	-8.86 (-23.22, 5.9)	34.76 (25.56, 44.1)	-5.21 (-10.89, 0.42)	minoxidil(topical)1%	5.54 (1, 10.05)	4.36 (0.44, 8.27)	-6.6 (-10.9, -2.35)
18.79 (10.63, 26.94)	-14.4 (-28.07, -0.42)	29.25 (21.16, 37.33)	-10.74 (-15.96, -5.6)	-5.54 (-10.05, -1)	minoxidil(topical)2%	-1.18 (-7.13, 4.84)	-12.13 (-14.85, -9.48)
19.98 (9.88, 30.05)	-13.22 (-28.14, 2.08)	30.4 (20.44, 40.47)	-9.57 (-16.44, -2.72)	-4.36 (-8.27, -0.44)	1.18 (-4.84, 7.13)	minoxidil(topical)5%	-10.94 (-16.77, -5.2)
30.94 (22.38, 39.49)	-2.25 (-16.22, 12.03)	41.37 (32.9, 49.95)	1.41 (-3.58, 6.32)	6.6 (2.35, 10.9)	12.13 (9.48, 14.85)	10.94 (5.2, 16.77)	vehicle or placebo

eFigure 20. League table for our second endpoint (i.e., ‘outcome 2’) (for androgenetic alopecia that is MODERATE). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia **that is MODERATE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 2%, is significantly more efficacious than vehicle or placebo (mean difference = 12.13, p<0.05).

finasteride(oral)1mg	-33.19 (-47.39, -19.21)	10.43 (2.22, 18.63)	-29.62 (-39.35, -20.04)	-24.46 (-33.91, -15.1)	-18.87 (-27.09, -10.67)	-20.11 (-30.27, -9.99)	-20.31 (-35.23, -2.76)
33.19 (19.21, 47.39)	minoxidil(oral)0.25mg	43.6 (29.74, 57.82)	3.54 (-11.25, 18.52)	8.73 (-5.85, 23.48)	14.35 (0.58, 28.32)	13.11 (-1.93, 28.36)	13.01 (-5.9, 33.72)
-10.43 (-18.63, -2.22)	-43.6 (-57.82, -29.74)	minoxidil(oral)5mg	-40.04 (-49.82, -30.4)	-34.86 (-44.32, -25.53)	-29.28 (-37.39, -21.15)	-30.53 (-40.65, -20.38)	-30.75 (-45.55, -13.2)
29.62 (20.04, 39.35)	-3.54 (-18.52, 11.25)	40.04 (30.4, 49.82)	minoxidil(topical)0.1%	5.16 (-0.46, 10.83)	10.77 (5.58, 15.97)	9.52 (2.66, 16.44)	9.2 (-4.5, 26.3)
24.46 (15.1, 33.91)	-8.73 (-23.48, 5.85)	34.86 (25.53, 44.32)	-5.16 (-10.83, 0.46)	minoxidil(topical)1%	5.6 (1.05, 10.15)	4.36 (0.46, 8.27)	4.04 (-9.37, 20.92)
18.87 (10.67, 27.09)	-14.35 (-28.32, -0.58)	29.28 (21.15, 37.39)	-10.77 (-15.97, -5.58)	-5.6 (-10.15, -1.05)	minoxidil(topical)2%	-1.24 (-7.24, 4.8)	-1.58 (-13.69, 14.16)
20.11 (9.99, 30.27)	-13.11 (-28.36, 1.93)	30.53 (20.38, 40.65)	-9.52 (-16.44, -2.66)	-4.36 (-8.27, -0.46)	1.24 (-4.8, 7.24)	minoxidil(topical)5%	-0.3 (-14.35, 17.03)
20.31 (2.76, 35.23)	-13.01 (-33.72, 5.9)	30.75 (13.2, 45.55)	-9.2 (-26.3, 4.5)	-4.04 (-20.92, 9.37)	1.58 (-14.16, 13.69)	0.3 (-17.03, 14.35)	vehicle or placebo

eFigure 21. League table for our second endpoint (i.e., ‘outcome 2’) (for androgenetic alopecia that is SEVERE). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 24 weeks of therapy in men with androgenetic alopecia **that is SEVERE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, finasteride(oral)1mg, is significantly more efficacious than vehicle or placebo (mean difference = 20.31, p<0.05).

finasteride(oral)1mg	-0.1 (-10.61, 9.22)	-15.47 (-24.37, -6.74)	-11.5 (-25.7, 2.71)	-6.42 (-18.2, 9.59)
0.1 (-9.22, 10.61)	finasteride(oral)5mg	-15.3 (-28.33, -1.82)	-11.28 (-28.36, 6.15)	-6.45 (-24.68, 18.17)
15.47 (6.74, 24.37)	15.3 (1.82, 28.33)	minoxidil(topical)2%	4 (-7.03, 15.05)	9.16 (-6.26, 27.5)
11.5 (-2.71, 25.7)	11.28 (-6.15, 28.36)	-4 (-15.05, 7.03)	minoxidil(topical)3%	5.26 (-14.14, 26.72)
6.42 (-9.59, 18.2)	6.45 (-18.17, 24.68)	-9.16 (-27.5, 6.26)	-5.26 (-26.72, 14.14)	vehicle or placebo

eFigure 22. League table for our third endpoint (i.e., ‘outcome 3’) (for androgenetic alopecia that is MILD). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 48 weeks of therapy in men with androgenetic alopecia **that is MILD**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, finasteride (oral) 1mg, is significantly more efficacious than minoxidil(topical) 2% (mean difference = 15.47 p<0.05).

finasteride(oral)1mg	4.89 (-7.14, 15.47)	-15.49 (-24.33, -6.6)	-11.44 (-25.67, 2.77)	-16.58 (-27.53, -7.45)
-4.89 (-15.47, 7.14)	finasteride(oral)5mg	-20.35 (-34.21, -5.57)	-16.26 (-34.05, 2.23)	-21.51 (-27.39, -15.56)
15.49 (6.6, 24.33)	20.35 (5.57, 34.21)	minoxidil(topical)2%	4.07 (-7.1, 15.28)	-1.16 (-14.77, 11.42)
11.44 (-2.77, 25.67)	16.26 (-2.23, 34.05)	-4.07 (-15.28, 7.1)	minoxidil(topical)3%	-5.24 (-22.73, 11.47)
16.58 (7.45, 27.53)	21.51 (15.56, 27.39)	1.16 (-11.42, 14.77)	5.24 (-11.47, 22.73)	vehicle or placebo

eFigure 23. League table for our third endpoint (i.e., ‘outcome 3’) (for androgenetic alopecia that is MODERATE). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 48 weeks of therapy in men with androgenetic alopecia **that is MODERATE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, finasteride (oral) 1mg, is significantly more efficacious than minoxidil(topical) 2% (mean difference = 15.5 p<0.05).

finasteride(oral)1mg	8.34 (0.89, 15.97)	-15.49 (-24.38, -6.61)	-11.43 (-25.61, 2.72)	-35.48 (-57.08, -16.59)
-8.34 (-15.97, -0.89)	finasteride(oral)5mg	-23.87 (-35.42, -12.15)	-19.84 (-35.81, -3.76)	-43.79 (-69.51, -21.33)
15.49 (6.61, 24.38)	23.87 (12.15, 35.42)	minoxidil(topical)2%	4.06 (-7.07, 15.2)	-19.98 (-43.31, 1.23)
11.43 (-2.72, 25.61)	19.84 (3.76, 35.81)	-4.06 (-15.2, 7.07)	minoxidil(topical)3%	-24.06 (-49.76, 0.1)
35.48 (16.59, 57.08)	43.79 (21.33, 69.51)	19.98 (-1.23, 43.31)	24.06 (-0.1, 49.76)	vehicle or placebo

eFigure 24. League table for our third endpoint (i.e., ‘outcome 3’) (for androgenetic alopecia that is SEVERE). This figure presents all pairwise comparisons in the network for change in total hair count (per cm²) after 48 weeks of therapy in men with androgenetic alopecia **that is SEVERE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, finasteride (oral) 1mg, is significantly more efficacious than minoxidil(topical) 2% (mean difference = 15.50 p<0.05).

finasteride(oral)1mg	-31.94 (-40.19, -23.82)	-20.43 (-36.41, -4.52)	-26.03 (-36.09, -16.12)	-56 (-5761.12, 4714.82)
31.94 (23.82, 40.19)	minoxidil(topical)2%	11.55 (-2.03, 25.03)	5.91 (0.16, 11.61)	-23.95 (-5731.02, 4747.77)
20.43 (4.52, 36.41)	-11.55 (-25.03, 2.03)	minoxidil(topical)3%	-5.65 (-20.28, 9.07)	-35.5 (-5741.34, 4737.69)
26.03 (16.12, 36.09)	-5.91 (-11.61, -0.16)	5.65 (-9.07, 20.28)	minoxidil(topical)5%	-29.46 (-5736.01, 4742.56)
56 (-4714.82, 5761.12)	23.95 (-4747.77, 5731.02)	35.5 (-4737.69, 5741.34)	29.46 (-4742.56, 5736.01)	vehicle or placebo

eFigure 25. League table for our fourth endpoint (i.e., ‘outcome 4’) (for androgenetic alopecia that is MILD). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 48 weeks of therapy in men with **androgenetic alopecia that is MILD**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 5% is significantly more efficacious than minoxidil (topical) 2% (mean difference = 5.91, p<0.05).

finasteride(oral)1mg	-32.03 (-40.21, -23.78)	-20.44 (-36.33, -4.61)	-26.07 (-36.06, -15.99)	-40.77 (-75.43, -10.46)
32.03 (23.78, 40.21)	minoxidil(topical)2%	11.57 (-2.04, 25.1)	5.93 (0.15, 11.68)	-8.73 (-43.01, 21.21)
20.44 (4.61, 36.33)	-11.57 (-25.1, 2.04)	minoxidil(topical)3%	-5.6 (-20.41, 9.08)	-20.27 (-56.22, 11.31)
26.07 (15.99, 36.06)	-5.93 (-11.68, -0.15)	5.6 (-9.08, 20.41)	minoxidil(topical)5%	-14.64 (-49.13, 15.16)
40.77 (10.46, 75.43)	8.73 (-21.21, 43.01)	20.27 (-11.31, 56.22)	14.64 (-15.16, 49.13)	vehicle or placebo

eFigure 26. League table for our fourth endpoint (i.e., ‘outcome 4’) (for androgenetic alopecia that is MODERATE). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 48 weeks of therapy in men with **androgenetic alopecia that is MODERATE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 5% is significantly more efficacious than minoxidil (topical) 2% (mean difference = 5.93, p<0.05).

finasteride(oral)1mg	-32 (-40.2, -23.87)	-20.45 (-36.43, -4.62)	-26.08 (-36.07, -16.15)	-40.64 (-157.11, 66.96)
32 (23.87, 40.2)	minoxidil(topical)2%	11.56 (-2, 25.21)	5.93 (0.17, 11.7)	-8.64 (-124.81, 98.17)
20.45 (4.62, 36.43)	-11.56 (-25.21, 2)	minoxidil(topical)3%	-5.64 (-20.5, 9.18)	-20.18 (-136.34, 87.04)
26.08 (16.15, 36.07)	-5.93 (-11.7, -0.17)	5.64 (-9.18, 20.5)	minoxidil(topical)5%	-14.56 (-130.56, 92.12)
40.64 (-66.96, 157.11)	8.64 (-98.17, 124.81)	20.18 (-87.04, 136.34)	14.56 (-92.12, 130.56)	vehicle or placebo

eFigure 27. League table for our fourth endpoint (i.e., ‘outcome 4’) (for androgenetic alopecia that is SEVERE). This figure presents all pairwise comparisons in the network for change in terminal hair count (per cm²) after 48 weeks of therapy in men with **androgenetic alopecia that is SEVERE**. Each point estimate represents the mean difference, and the values in parentheses is the corresponding 95% credible interval. Yellow coloured cells represent significant (p<0.05) comparisons; each cell compares the column against the row. For example, minoxidil (topical) 5% is significantly more efficacious than minoxidil (topical) 2% (mean difference = 5.93, p<0.05).

References

1. Whiting D. *Hair Growth and Disorders*. (Blume-Peytavi U, Tosti A, Trüeb R, eds.). Springer; 2008. doi:10.1007/978-3-540-46911-7
2. Hugh Rushton D, Norris MJ, Van Neste D. Hair regrowth in male and female pattern hair loss does not involve the conversion of vellus hair to terminal hair. *Exp Dermatol*. 2016;25(6):482-484. doi:10.1111/exd.12945
3. Van Neste D. Placebo-controlled dose-effect studies with topical minoxidil 2% or 5% in male-patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol. *Ski Res Technol Off J Int Soc Bioeng Ski [and] Int Soc Digit Imaging Ski [and] Int Soc Ski Imaging*. 2020;26(4):542-557. doi:10.1111/srt.12827